Charts

Gainers HTG Molecular Diagnostics (NASDAQ:HTGM) shares moved upwards by 33.0% to $6.01 during Wednesday's after-market session. This ...

Gainers Bright Green (NASDAQ:BGXX) shares increased by 251.2% to $1.83 during Wednesday's regular session. The current volume of 81.8 ...

Gainers Nymox Pharmaceutical (NASDAQ:NYMX) shares rose 21.8% to $0.5 during Monday's after-market session. The market value of their ...

Gainers Vaccitech (NASDAQ:VACC) shares rose 8.5% to $3.2 during Friday's after-market session. The company's market cap stands at ...

Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) stock rose 80.0% to $2.16 during Wednesday's pre-market session. The company's market cap ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's time to start off the day with an overview of the biggest pre-market stock movers traders need to know about on Wednesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Gainers Sotera Health Company (NASDAQ: SHC) shares jumped 92% to $16.59 after the company announced its subsidiaries have reached ...

Gainers Sotera Health (NASDAQ:SHC) stock moved upwards by 86.9% to $16.15 during Tuesday's regular session. The current volume of 38.4 ...

The Peninsula company's plan to close by the end of the first quarter is atypical in a biotech industry where executives try to keep their companies alive to the next milestone in order to raise more money.

Gainers Prenetics Global (NASDAQ:PRE) stock rose 74.7% to $3.25 during Tuesday's pre-market session. The market value of their ...

Gainers VYNE Therapeutics Inc. (NASDAQ: VYNE) rose 82.2% to $0.35 in pre-market trading after the company said first vitiligo ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're starting off the day with an overview of the biggest pre-market stock movers traders need to know about for Tuesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 150 points on Monday. The Dow traded ...

Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company ...

Gainers CinCor Pharma (NASDAQ:CINC) shares increased by 148.0% to $29.22 during Monday's regular session. As of 12:30 EST, CinCor ...

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Monday. The Dow traded up ...

Calithera Biosciences Inc(NASDAQ: CALA) announced that its Board of Directors has determined that it is in the best interests ...

U.S. stocks traded higher this morning, with the Dow Jones gaining around 150 points on Monday. Following the market opening Monday, ...

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), today announced that its Board of Directors has determined, after extensive consideration of potential strategic alternatives, that it is in the best interests of its shareholders to dissolve the Company and liquidate its assets, following an orderly wind down of the company’s operations. In order to reduce costs and in connection with the planned dissolution, Calithera is discontinuing all

-- Conference Call and Webcast Scheduled for 5:00 p.m. ET on Monday, November 14, 2022 --SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the third quarter ended September 30, 2022. “Earlier in the fourth quarter, we were very pleased to announce that we received FDA Fast Track designation for sapanisertib. This designation facilitate

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced Company’s third quarter 2022 financial results will be released on Monday, November 14, 2022. Company management will host a conference call on Monday, November 14, 2022, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights. Participants who wi

The recent setback faced by KalVista (KALV) for terminating the phase II KOMPLETE study evaluating KVD824 for prophylactic treatment of hereditary angioedema hurts the stock.

Gainers Statera BioPharma (NASDAQ:STAB) stock increased by 64.8% to $0.23 during Thursday's pre-market session. The ...

Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it ...

Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) gained 641% to $2.0207 after the company announced it will be acquired by ...

Enrollment ongoing in Phase 2 study evaluating sapanisertib, a dual mTORC1/2 inhibitor, in patients with squamous non-small cell lung cancer harboring a NRF2 mutationSOUTH SAN FRANCISCO, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track designation for the company’s investigational mTORC 1/2 inhibitor sapaniserti

The FDA Oncologic Drugs Advisory Committee votes against Spectrum's (SPPI) poziotinib for treating non-small cell lung cancer in previously treated patients with HER2 exon 20 mutations. Stock down.

Pacira's (PCRX) phase III study evaluating its marketed drug, Exparel, as a single-dose sciatic nerve block in the popliteal fossa for bunionectomy meets primary and secondary endpoints.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips You probably haven't heard of any of these penny stocks, but their fundamentals make them worth a look for investors with speculative capital. The post 3 Penny Stocks With Surprisingly Superior Fundamentals appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company’s founder, president and chief executive officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference, being held September 12-14 both virtually and in New York, NY. The presentation will be available for on-demand viewing starting Monday, Septem

Gainers American Virtual Cloud Technologies, Inc. (NASDAQ: AVCT) climbed 156.3% to close at $0.3750 on Monday. American Virtual ...

HC Wainwrightupdated its model onCalithera Biosciences Inc(NASDAQ: CALA), reflecting therecent Q2 ...

Upgrades According to Argus Research, the prior rating for AstraZeneca PLC (NASDAQ:AZN) was changed from Hold to Buy. For the second ...

Gainers Micro Focus International plc (NYSE: MFGP) shares surged 92% to close at $6.01 on Friday after the company reached an ...

Gainers Minerva Neurosciences (NASDAQ:NERV) stock rose 44.6% to $9.44 during Friday's regular session. Minerva ...

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

CALA earnings call for the period ending June 30, 2022.

-- Conference Call and Webcast Scheduled for 5:00 p.m. ET on Monday, August 15, 2022 --SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the second quarter ended June 30, 2022. “We continue to deliver on our commitment to efficiently advance our clinical programs, successfully initiating two new clinical trials and sharing program upda

Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is likely to report earnings for its second ...

Calithera Biosciences (NASDAQ:CALA) is set to give its latest quarterly earnings report on Monday, 2022-08-15. Here's what ...

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced Company’s second quarter 2022 financial results will be released on Monday, August 15, 2022. Company management will host a conference call on Monday, August 15, 2022, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights. Participants who wish

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Reverse stock splits are not that common and often are associated with some trouble brewing at the company. Therefore, one must do a thorough study before deciding what to do what with the stock of a company that just announced a reverse split. The post What Is a Reverse Stock Split and How Does It Work? appeared first on InvestorPlace. More From InvestorPlace $200 Oil Sooner Than You Think – Buy This Now The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 in savings or $5 million. Do this now.

Gainers Pagaya Technologies Ltd. (NASDAQ: PGY) shares climbed 129.6% to close at $6.20 on Wednesday. Pagaya Technologies is ...

-- Overview of phase 2 study evaluating SYK inhibitor mivavotinib in patients with relapsed/refractory non-GCB (ABC) diffuse large B-cell lymphoma -- -- First data from phase 1 investigator-sponsored clinical study of TORC 1/2 inhibitor sapanisertib in combination with telaglenastat in patients with non-small cell lung cancer -- SOUTH SAN FRANCISCO, Calif., July 13, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company

-- Patients with tumors harboring NRF2-mutations have a poorer prognosis and no available targeted therapies -- SOUTH SAN FRANCISCO, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced that it has enrolled the first patient in a phase 2 clinical trial of sapanisertib (CB-228) in patients with relapsed/refractory NRF2 (NFE2L2)-mutated squamous non-small cell lung cancer (sqNSCLC). NRF

Calithera Biosciences, Inc. (NASDAQ: CALA) initiates dosing first patient in the phase 2 clinical trial evaluating its spleen tyrosine ...

-- Novel biomarker will be used to identify patients in genetically defined subgroup associated with poorer outcomes -- Study will evaluate SYK inhibitor both in patients with wild-type disease and those with tumors that harbor MYD88 or CD79b mutations SOUTH SAN FRANCISCO, Calif., June 23, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, announced that the first patient has been enrolled in a multicenter phase 2

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's time for another breakdown of the biggest pre-market stock movers as we go over the latest news for Thursday morning. The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace $200 Oil Sooner Than You Think – Buy This Now Stock Prodigy Who Found NIO at $2… Says Buy THIS Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 in savings or $5 million. Do this now.

Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) rose 92.9% to $3.28 in pre-market trading following’s Wednesday ...

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Pfizer Halts Enrollment In ...

Gainers Comera Life Sciences Holdings, Inc. (NASDAQ: CMRA) gained 126.5% to settle at $2.65 on Tuesday. Revlon, Inc. (NYSE: REV) ...

Gainers View, Inc. (NASDAQ: VIEW) rose 18.5% to $2.05 in pre-market trading after declining 5% on Wednesday. Kiora ...

Gainers Symbotic Inc. (NASDAQ: SYM) shares surged 120.6% to settle at $20.07 on Wednesday. Symbotic reported the completion of ...

On Tuesday, shares of Calithera Biosciences (NASDAQ: CALA) experienced volatile short activity. After the activity, the stock price went ...

Gainers Athenex (NASDAQ:ATNX) shares increased by 30.5% to $0.62 during Monday's pre-market session. The market ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back and get ready for another busy week of trading as we start it off with the biggest pre-market stock movers for Monday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) rose 25.2% to $2.09 in pre-market trading after gaining around 10% on ...